US EditionPublished • loading... • Updated
Cizzle Biotechnology Expands North American Rollout Of CIZ1B Lung Cancer Test
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cizzle Biotechnology Expands North American Rollout Of CIZ1B Lung Cancer Test
Cizzle Biotechnology Holdings Plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has announced further progress on the commercial roll out of the Company’s CIZ1B biomarker test in North America by its exclusive licencing partner Cizzle Bio Inc. BIO is now completing validation of the test with its new clinical diagnostics laboratory group, Omni Health Diagnostics, as part of a national expansion strategy based on Omni’s act…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
